Comparative Pharmacology
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus ISOCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus ISOCAINE HYDROCHLORIDE.
HEAVY SOLUTION NUPERCAINE vs ISOCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heavy solution nupercaine (dibucaine) is a potent, long-acting amide local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the propagation of action potentials and preventing nerve impulse conduction.
Isocaine hydrochloride is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials.
Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.
1-2% solution infiltrated subcutaneously or locally, maximum dose 4.5 mg/kg (with epinephrine) or 3.0 mg/kg (without epinephrine), not to exceed 300 mg.
None Documented
None Documented
Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Terminal elimination half-life is approximately 2.5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged to 6–8 hours; in severe renal impairment, half-life may extend to 4–6 hours.
Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Renal: Approximately 90% of the dose is excreted as metabolites (primarily conjugated with glucuronic acid) in urine. Fecal: About 10% eliminated unchanged or as metabolites in feces. Biliary excretion is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic